Skip to main content

Table 3 Mean changes in HRQoL scores from baseline to study phase completion (week 16) by categories of change in SDAI, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

  SDAI Categories of change
  > +10 (n = 4) +10 to -10 (n = 67) -10 to -21 (n = 57) -22 to -57 (n = 53) F p-value
PRO Instruments       
SF-36       
Physical functioning -7.5 (40.9) 2.5 (14.3) 6.5 (16.5) 14.8 (20.2) 5.8 0.0008
Role physical 0.0 (15.3) 1.7 (18.9) 9.5 (20.3) 20.5 (24.2) 8.2 0.0000
Bodily pain -13.0 (11.2) 0.4 (14.5) 11.4 (17.0) 23.3 (19.9) 20.6 0.0000
General health -10.0 (17.3) -1.1 (13.5) 3.1 (13.7) 10.2 (13.8) 8.0 0.0001
Vitality -1.6 (25.2) 0.2 (16.8) 5.0 (18.3) 17.5 (20.9) 8.9 0.0000
Social functioning -28.1 (21.3) -0.4 (21.4) 3.7 (26.0) 16.3 (26.7) 7.3 0.0001
Role emotional -14.6 (14.2) -0.4 (22.6) 5.1 (26.6) 11.6 (28.2) 3.0 0.0332
Mental health -1.3 (7.5) -1.0 (15.2) 5.4 (18.5) 9.4 (20.3) 3.6 0.0156
Physical summary -3.0 (10.5) 0.8 (4.6) 3.2 (5.4) 7.6 (7.1) 15.5 0.0000
Mental summary -4.7 (9.6) -0.7 (8.5) 1.9 (10.6) 5.3 (12.1) 3.8 0.0108
HAQ-DI 0.16 (0.07) -0.04 (0.31) -0.25 (0.39) -0.53 (0.52) 15.6 0.0000
FACIT-Fatigue -6.8 (5.2) 0.6 (7.2) 3.5 (7.3) 8.3 (7.3) 14.1 0.0000